Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 13/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 9/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769831 | 0.91 | ADRB2 (0.58) | ADRB2ADRB3ADRB1 | |
| SCHEMBL18769861 | 0.88 | ADRB2 (0.63) | ADRB2ADRB3ADRB1 | |
| SCHEMBL18769891 | 0.85 | ADRB2 (0.55) | ADRB2ADRB3ADRB1 | |
| SCHEMBL7149119 | 0.83 | ADRB3 (0.54) | ADRB2ADRB3ADRB1 | |
| SCHEMBL7149117 | 0.83 | ADRB3 (0.54) | ADRB2ADRB3ADRB1 | |
| SCHEMBL18792027 | 0.82 | ADRB2 (0.77) | ADRB2ADRB3ADRB1 | |
| SCHEMBL10893319 | 0.81 | HTT (0.53) | ADRB2ADRB3ADRB1HTT | |
| SCHEMBL18769904 | 0.80 | ADRB2 (0.48) | ADRB2ADRB3ADRB1 | |
| SCHEMBL7149115 | 0.76 | ADRB2 (0.75) | ADRB2ADRB3ADRB1 | |
| SCHEMBL7937104 | 0.76 | ADRB2 (0.75) | ADRB2ADRB3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | claimed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | claimed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | claimed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3371181-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | Onco Therapies LLC (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070052-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | ONCO THERAPIES LLC (US) | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337889-A1 | COMPOSITIONS AND METHODS OF REGULATING CANCER RELATED DISORDERS AND DISEASES | BRCA1, VHL, TP53 | ADRB2 4152/4885ADRB3 3370/4885ADRB1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.